menu search

Why allakos stock was heating up today

Allakos is barreling toward two mid-stage data readouts that could alter its long-term outlook. An anal...

March 7, 2023, 4:05 pm

Annexon reports fourth quarter and year-end 2022 financial results and reiterates anticipated milestones

Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023 Oral Small Molecule ANX1502, for Autoimmu...

March 6, 2023, 11:30 am

Keros therapeutics: market rewarding ker-050 trial momentum

Data is promising for KROS' KER-050 compound; investors are rewarding the company on its novel hypotheses. We performed a deep dive on its most recent...

February 10, 2023, 11:36 pm

Crinetics pharmaceuticals to present corporate and clinical update at 41st annualĀ j.p. morgan healthcare conference

Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in acromegaly approach topline data ...

January 9, 2023, 8:01 am

Gsk, astrazeneca: will the two uk drugs giants ride the us$74bn pharma wave or will they be left beached?

The global pharma sector is expected to see clinical trial readouts that could potentially de-risk appr...

January 6, 2023, 7:54 am

Editas: end of year data readouts for scd and rare eye disease studies

Results from phase 1/2 BRILLIANCE study using EDIT-101 (Cas9 nuclease) for the treatment of patients with Leber Congenital Amaurosis 10 expected 2nd h...

August 23, 2022, 6:24 am

Poseida therapeutics: even after recent partnership, additional upside possible

Poseida Therapeutics is developing P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors; data ...

August 3, 2022, 3:09 pm

Cardiff oncology: upcoming readouts and several green lights

Cardiff Oncology started taking a beating from the early days of the biotech bear market, in September 2021. The company is the first to correctly tar...

June 7, 2022, 10:51 am

Biogen stock slides 2% after it withdraws authorization application with eu regulator

Biogen Inc. shares BIIB, -2.71% fell 2% Friday, after the company said it has withdrawn the marketing authorization application for its controversial ...

April 22, 2022, 10:44 am

Will these pharma giants pop or flop on clinical study readouts?

Do results from an important clinical trial affect the stock price of pharma companies? We're about to find out, as several ...

April 12, 2022, 3:05 pm

7 biotech stocks to buy with key catalysts for april

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical ...

April 5, 2022, 6:59 am

Arbutus biopharma; long-term hold with advancements into several areas of interest

Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for He...

March 7, 2022, 4:33 pm


Search within

Pages Search Results: